Understanding and Prevention of “Therapy-” Induced Dyskinesias
L-dopa is the most effective, currently available treatment for Parkinson’s disease (PD), but it leads to the development of involuntary movements known as L-dopa-induced dyskinesia (LID) in the majority of patients after long-term use. Both gene and cell therapy approaches are the subject of multip...
Saved in:
Main Authors: | Iciar Aviles-Olmos, Zinovia Kefalopoulou, Thomas Foltynie |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2012-01-01
|
Series: | Parkinson's Disease |
Online Access: | http://dx.doi.org/10.1155/2012/640815 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Critical Aspects of Clinical Trial Design for Novel Cell and Gene Therapies
by: Zinovia Kefalopoulou, et al.
Published: (2011-01-01) -
Dyskinesia in Parkinson's Disease Therapy
by: Anna Rosa Carta, et al.
Published: (2012-01-01) -
Clinical Aspects and Management of Levodopa-Induced Dyskinesia
by: Nicola Tambasco, et al.
Published: (2012-01-01) -
Corticostriatal Plastic Changes in Experimental L-DOPA-Induced Dyskinesia
by: Veronica Ghiglieri, et al.
Published: (2012-01-01) -
Paroxysmal Nonkinesigenic Dyskinesia with Tremor
by: Robert Fekete
Published: (2013-01-01)